Stay updated on Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Sign up to get notified when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.

Latest updates to the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded B-cell chronic lymphocytic leukemia as a keyword/condition term and included Genetic and Rare Diseases Information Center as a resources entry. These updates improve searchability and provide readers with additional background information.SummaryDifference0.2%

- Check19 days agoChange DetectedThe page's revision history now shows the addition of v3.5.0 and the removal of v3.4.3.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded Revision: v3.4.2. The prior funding-status notice and Revision: v3.4.1 were removed.SummaryDifference0.5%

- Check69 days agoChange DetectedAdded a government funding notice noting potential delays in updates and the NIH Clinical Center's status, with guidance to check cc.nih.gov and opm.gov. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check76 days agoChange DetectedThe page now includes a glossary toggle and new metadata fields: Last Update Submitted that Met QC Criteria and Last Update Posted, along with a revision indicator: Revision: v3.4.0. Older items Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.3%

Stay in the know with updates to Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.